Former Yaupon Therapeutics Raises $15 Million In Debt To Prepare To Commercialize Its First Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Now called Ceptaris, the company is awaiting FDA approval of mechlorethamine gel, a topical formulation of a cytotoxin, for early-stage CTCL.
You may also be interested in...
Actelion, Under Pressure To Diversify, Eyes Rare Disease Start-Up Ceptaris
Actelion is paying a $25 million upfront for an option to acquire Ceptaris Therapeutics, contingent upon the latter’s receiving FDA approval for its only asset, Valchlor, which faces an August PDUFA date. If the deal closes, Ceptaris will receive another $225 million plus milestones from the Swiss-based biotech.
Financings Of The Fortnight: Could California’s Regenerative Medicine Ballot Initiative Pass Today?
Plus news on recent financings by bluebird bio, Puma Biotechnology, Atara Biotherapeutics and Aclaris Therapeutics.
Vicept Management, VCs Team Up Again To Launch Aclaris With $21M
Newly launched dermatology start-up Aclaris brings the band back together, as Vicept’s core management and VCs begin a new endeavor in a sometimes-neglected sector.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: